Clinical Trial Update: Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating adjuvant sacituzumab govitecan in combination with nivolumab for high-risk, resected muscle-invasive urothelial carcinoma; recruitment …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)
• nivolumab (nivolumab)

Snippet

Sponsor: University of California, Irvine | Conditions: Urothelial Carcinoma, Muscle-invasive Bladder Cancer | Phase 2 | Status: RECRUITING